Johnson & Johnson (NYSE:JNJ) Shares Acquired by Handelsbanken Fonder AB

Handelsbanken Fonder AB boosted its position in Johnson & Johnson (NYSE:JNJ) by 290.9% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,114,004 shares of the company’s stock after purchasing an additional 829,053 shares during the period. Johnson & Johnson comprises approximately 1.3% of Handelsbanken Fonder AB’s holdings, making the stock its 8th largest position. Handelsbanken Fonder AB’s holdings in Johnson & Johnson were worth $156,662,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in JNJ. Capital World Investors lifted its position in Johnson & Johnson by 182.9% in the first quarter. Capital World Investors now owns 21,195,989 shares of the company’s stock valued at $2,779,435,000 after purchasing an additional 13,703,905 shares during the period. Nordea Investment Management AB lifted its position in Johnson & Johnson by 88.0% in the second quarter. Nordea Investment Management AB now owns 17,222,162 shares of the company’s stock valued at $2,382,514,000 after purchasing an additional 8,062,204 shares during the period. Wellington Management Group LLP lifted its position in Johnson & Johnson by 10.8% in the first quarter. Wellington Management Group LLP now owns 30,556,662 shares of the company’s stock valued at $4,006,895,000 after purchasing an additional 2,968,879 shares during the period. Massachusetts Financial Services Co. MA lifted its position in Johnson & Johnson by 7.7% in the first quarter. Massachusetts Financial Services Co. MA now owns 29,526,058 shares of the company’s stock valued at $3,871,753,000 after purchasing an additional 2,118,870 shares during the period. Finally, Capital International Investors lifted its position in Johnson & Johnson by 13.6% in the first quarter. Capital International Investors now owns 16,726,965 shares of the company’s stock valued at $2,193,411,000 after purchasing an additional 2,004,688 shares during the period. Hedge funds and other institutional investors own 67.44% of the company’s stock.

A number of equities research analysts recently commented on the stock. Cantor Fitzgerald restated a “buy” rating and issued a $168.00 price objective on shares of Johnson & Johnson in a research report on Monday, August 3rd. ValuEngine raised shares of Johnson & Johnson from a “sell” rating to a “hold” rating in a report on Monday, August 3rd. Zacks Investment Research cut shares of Johnson & Johnson from a “hold” rating to a “sell” rating and set a $150.00 target price for the company. in a report on Tuesday, July 7th. Independent Research raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating and increased their target price for the company from $161.00 to $164.00 in a report on Monday, July 20th. Finally, Raymond James increased their target price on shares of Johnson & Johnson from $157.00 to $158.00 and gave the company an “outperform” rating in a report on Friday, July 17th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and eleven have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $163.00.

In other Johnson & Johnson news, EVP Kathryn E. Wengel sold 16,115 shares of Johnson & Johnson stock in a transaction on Wednesday, September 2nd. The shares were sold at an average price of $153.52, for a total value of $2,473,974.80. Following the transaction, the executive vice president now owns 66,658 shares in the company, valued at approximately $10,233,336.16. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Ashley Mcevoy sold 29,000 shares of Johnson & Johnson stock in a transaction on Tuesday, July 28th. The shares were sold at an average price of $147.47, for a total transaction of $4,276,630.00. Following the completion of the transaction, the executive vice president now owns 21,682 shares in the company, valued at approximately $3,197,444.54. The disclosure for this sale can be found here. 0.27% of the stock is currently owned by insiders.

JNJ stock traded up $0.34 during midday trading on Tuesday, hitting $148.69. The stock had a trading volume of 216,478 shares, compared to its average volume of 8,504,898. The firm has a market cap of $390.58 billion, a PE ratio of 21.77, a price-to-earnings-growth ratio of 3.27 and a beta of 0.68. The company has a debt-to-equity ratio of 0.40, a current ratio of 1.25 and a quick ratio of 0.99. Johnson & Johnson has a 12-month low of $109.16 and a 12-month high of $157.00. The company’s 50-day moving average price is $149.29 and its 200 day moving average price is $144.17.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Thursday, July 16th. The company reported $1.67 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.50 by $0.17. The firm had revenue of $18.34 billion during the quarter, compared to analysts’ expectations of $17.73 billion. Johnson & Johnson had a net margin of 22.69% and a return on equity of 35.21%. Johnson & Johnson’s revenue for the quarter was down 10.8% on a year-over-year basis. During the same period in the previous year, the company earned $2.58 EPS. As a group, sell-side analysts anticipate that Johnson & Johnson will post 7.85 EPS for the current year.

The company also recently announced a quarterly dividend, which was paid on Tuesday, September 8th. Shareholders of record on Tuesday, August 25th were paid a $1.01 dividend. The ex-dividend date of this dividend was Monday, August 24th. This represents a $4.04 annualized dividend and a yield of 2.72%. Johnson & Johnson’s payout ratio is currently 46.54%.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Featured Story: If I purchase shares through a brokerage account, am I the holder of record?

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.